AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01469052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (5 mg twice a day) in the fed state
Study NCT01469052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (15 mg once a day) in the fed state
Study NCT01469052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
Study NCT01469052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
Study NCT03008590 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: One 4.5 mg capsule each evening
Study NCT03008590 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One capsule each evening
Study NCT03492775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
Study NCT01884285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: AZD8186 monotherapy
Description: The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
Study NCT01884285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: AZD8186 monotherapy
Description: Part B will be at a dose(s) and schedule(s) at or below from Part A
Study NCT02387034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription
Description: Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
Study NCT02387034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General advice
Description: Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
Study NCT00867360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU-486)
Study NCT00867360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication
Study NCT03066479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Wearable activity \& sleep tracker.
Study NCT03066479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSA questionnaire
Description: Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
Study NCT03066479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: All participants will be undergoing a sleep study as part of their clinical care.
Study NCT02722798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Doses may be titrated to achieve the target peak serum phosphorus range
Study NCT00685464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Intravenous.
Study NCT00685464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Intracoronary
Study NCT00662272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone vaccine with JVRS-100 adjuvant
Description: One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
Study NCT00662272 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone vaccine
Description: One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
Study NCT00662272 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone vaccine
Description: One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
Study NCT04417348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retinoic acid
Description: To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
Study NCT04417348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Retinoic acid
Description: To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
Study NCT00746486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
Study NCT00746486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide placebo
Description: One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
Study NCT05651698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMan Intervention group
Description: The system uses wrist-band sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
Study NCT03141151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH: Healthy Bodies
Description: Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
Study NCT03141151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COACH: Strong Minds
Description: School Readiness Intervention focusing on literacy and parent skills
Study NCT02162615 — intervention group
Intervention type: DEVICE
Intervention: Restorelle Direct Fix A
Study NCT02162615 — intervention group
Intervention type: DEVICE
Intervention: Restorelle Direct Fix P
Study NCT02162615 — intervention group
Intervention type: PROCEDURE
Intervention: Native Tissue Repair Anterior
Study NCT02162615 — intervention group
Intervention type: PROCEDURE
Intervention: Native Tissue Repair Posterior
Study NCT02621190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: 25mg/m2 q3w
Study NCT04422730 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological evaluation
Description: Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
Study NCT02955940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg BID
Study NCT02955940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at the same dose provided in the parent study at the time of the rollover.
Study NCT02955940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib at the same dose provided in the parent study at the time of the rollover.
Study NCT01663662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Study NCT03492775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine belongs formally to the alkylators, but has been shown to have a unique mechanism of action. The dose limiting toxicity of bendamustine is its reversible suppression of bone marrow function with drops in leukocyte and thromobocyte counts.
Study NCT01616134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Korea red ginseng
Description: Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
Study NCT01616134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
Study NCT02280473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Optive® Gel Drops
Description: Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Study NCT02280473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REFRESH LIQUIGEL®
Description: REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Study NCT03268473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis
Study NCT03268473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control: Non-surgical periodontal therapy in Periodontitis
Study NCT04706416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetyl glucosamine (NAG)
Description: Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
Study NCT04706416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
Study NCT00749554 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Disc biacuplasty
Description: The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
Study NCT00749554 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham biacuplasty
Description: Probes not inserted into disc, no RF electricity applied.
Study NCT04496310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedicine versus usual care (face to face visit)
Study NCT00976573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT03596983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention
Description: * Sleep Diaries (Daily)~* Fitbit 24/7~* Phone/ video conference calls (weekly with study team)~* Epworth Sleepiness Scale (weekly)~* PROMIS fatigue scale-evening (weekly)
Study NCT01884285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C1: Abiraterone acetate combination with AZD8186
Description: Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
Study NCT02514980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Infraorbital nerve block using bupivacaine 0.25% on each side.
Study NCT02514980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Infraorbital nerve block using 0.5mg/kg ketamine on each side.
Study NCT01884285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part D1: AZD2014 combination with AZD8186
Description: Dose \& schedule finding of AZD8186 in combination with AZD2014
Study NCT01884285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part D2 AZD2014 combination with AZD8186
Description: Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
Study NCT01884285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C2: Abiraterone acetate combination with AZD8186
Description: Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
Study NCT01320579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-UCA 2.5% emulsion cream
Description: 2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
Study NCT01320579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-UCA 5% emulsion cream
Description: 5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
Study NCT01320579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for cis-UCA emulsion cream
Description: The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
Study NCT01320579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic® 0.1% ointment
Description: 0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
Study NCT00844298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib+mVPD
Description: 1. Induction:~   * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~  * Vincristine 2 mg iv push (d1, 8, 15, 22)~  * Prednisolone 60 mg/m2/day po (d1-28)~  * Nilotinib 400mg bid/d (d8-)~2. Consolidation A (cycle1)~   * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~  * Vincristine 2 mg iv (d1, 8)~  * Prednisolone 60 mg/m2/day po (d1-14)~  * Nilotinib 400mg bid/d~3. Consolidation B (cycles 2\&4)~   * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~  * Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~  * Nilotinib 400mg bid/d~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~  * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~  * Nilotinib 400mg bid/d~5. Maintenance~   ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~6. Consider alloHCT
Study NCT03867708 — intervention group
Intervention type: RADIATION
Intervention: ASD device closure
Description: transcatheter secundum ASD device closure
Study NCT02157415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uro-Tainer Polihexanide 0.02%
Description: Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
Study NCT01663662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04171115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly
Study NCT04372693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: impliminting Online Distance Learning
Description: as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
Study NCT00445055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Intravenous injection
Study NCT04171115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly
Study NCT02550275 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological test
Study NCT04388358 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
Description: All patients were treated with mixed formula of Chinese medicine for one month
Study NCT02677558 — intervention group
Intervention type: OTHER
Intervention: Transthoracic Echocardiography
Description: Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
Study NCT00680940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel & Cisplatin
Description: Chemotherapeutic agent
Study NCT00680940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w.
Description: Immunomodulator
Study NCT03960801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil group
Description: bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
Study NCT03960801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular blockade group
Description: Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
Study NCT02997891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: everyday activity
Description: To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
Study NCT02997891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cognitive performance
Description: Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
Study NCT05311072 — intervention group
Intervention type: PROCEDURE
Intervention: pulmonary endarterectomy or balloon pulmonary angioplasty
Description: A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
Study NCT00820885 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
Study NCT00820885 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
Study NCT02550275 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Study NCT02682563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg QD
Description: Dapagliflozin 10mg once daily for 12 weeks
Study NCT02682563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide 30mg QD
Description: Gliclazide30mg once daily for 12 weeks
Study NCT02710006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonohysterography
Description: Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
Study NCT03523871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: Patients will be on 8 weeks of Mavyret
Study NCT04558099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Described previously
Study NCT00816140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cravit based triple therapy
Description: Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days
Study NCT00816140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid based triple therapy
Description: Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days
Study NCT00820885 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
Study NCT02754089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhus Coriaria L.(Rhus)
Description: 500 mg twice daily after meals for 6 weeks
Study NCT02754089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg twice daily after meals for 6 weeks
Study NCT03273751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.